Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Skrahina, H. Hurevich, A. Astrauko, A. Skrahin, L. Surkova (Minsk, Belarus). MDR/XDR-TB treatment outcome. Eur Respir J 2009; 34: Suppl. 53, 210

Member's Comments

No comment yet.

Related content which might interest you: Clinical management improves the treatment outcome of MDR-TB patients Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 The effect of resection surgery on long-term treatment outcomes of patients with MDR/XDR-TB Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017 Long-term effectiveness of surgery treatment of TB patients Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Outcome of drug resistant TB in hospital settings-a comparision of individualized treatment based on past history of anti-TB drugs with culture sensitivity guided treatment Source: Eur Respir J 2006; 28: Suppl. 50, 589s Year: 2006 Standardized second-line anti-TB treatment of multidrug-resistant tuberculosis during pregnancy; maternal and neonatal safety and outcome Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010 Treatment outcomes for XDR TB patients with surgery Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Poor treatment outcomes of XDR-TB patients in resource-limited settings Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017 Year: 2017 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Source: Eur Respir J 2010; 36: 870-877 Year: 2010 Does gender has any effect on tuberculosis diagnosis and treatment outcomes? Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003